Trinity Biotech and Latch Medical partner on biosensor-guided drug delivery

Trinity Biotech plc announced on July 22, 2026 a strategic collaboration agreement with Latch Medical Limited, a medical technology company with an innovative intradermal drug delivery platform called Pharma Latch.¹

The two companies said they intend to combine data from Trinity Biotech's CGM+ wearable biosensor platform with Latch Medical's drug delivery technology to evaluate precision therapeutic solutions for diabetes, obesity and other metabolic conditions, exploring how real-time metabolic data from CGM+ could help guide and optimize drug delivery.¹

As part of the deal, Trinity Biotech has agreed in principle to invest equity in Latch Medical, a company that has already drawn investment from other established players in the drug delivery industry.¹ Perceptive Advisors, described as Trinity Biotech's largest financial investor, is supporting this planned investment.¹

On the technology itself, Latch Medical's device is described as a hollow microneedle system built to deliver injectable therapies into the skin with precision and repeatability.¹ It is meant to work with a range of liquid drug formulations and volumes, in both clinical and home settings.¹

The filing notes Pharma Latch products remain in development and pre-approval, not yet cleared for sale in the US, EU or elsewhere, though the Pharma Latch HCP device (Pharma Latch Hollow) is being prepared for regulatory submission.¹

Trinity Biotech also pointed to earlier work, saying the new collaboration builds on previously announced CGM+ clinical trial data related to detecting nocturnal compression lows.¹ The company describes itself as a commercial-stage diagnostics and diabetes management business that recently entered the wearable biosensor market through its acquisition of biosensor assets from Waveform Technologies Inc.¹